From AI Platform to the Clinic: Making the Decisions That Change a Biotech

<p>What happens when a biotech company realises that its next stage of growth requires a completely different approach?</p><p>In this episode of <em>She Leads Biotech</em>, I&#39;m joined by <strong>Beverley Carr, Chief Business and Operating Officer at CHARM Therapeutics</strong>, to explore the realities of transforming promising science into a clinical-stage business.</p><p>Beverley shares the decisions behind CHARM&#39;s shift from a broad AI drug discovery platform to a focused oncology programme, the challenges of restructuring a business for its next stage, and why having the right people in place matters just as much as having great science.</p><p>We also discuss the real value of AI in drug discovery, the importance of making difficult decisions early, and Beverley&#39;s own journey from chemistry to biotech leadership.</p><p>It&#39;s a conversation about adaptability, courage and recognising when the path forward requires doing things differently.</p><p><strong>Because sometimes the most important leadership decision isn&#39;t what to pursue next, but what you&#39;re prepared to leave behind.</strong></p><p>🎧 Listen now on <em>She Leads Biotech</em>.</p><p>#SheLeadsBiotech #BiotechLeadership #WomenInBiotech #DrugDiscovery #LifeSciences</p><p></p>